PROTEOMICS INTERNATIONAL LABORATORIES LIMITED Proteomics International Laboratories Limited Stock
Equities
PIQ
AU000000PIQ0
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.09 AUD | -2.68% |
|
-8.40% | +21.79% |
| Mar. 25 | Proteomics International Signs Agreement with University of Oxford for Endometriosis Study | MT |
| Mar. 19 | Proteomics Says PromarkerD's US Launch Delayed | MT |
| Sales 2024 * | 2.8M 1.8M | Sales 2025 * | 5.9M 3.79M | Capitalization | 143M 91.54M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -4.49M | Net income 2025 * | -5M -3.21M | EV / Sales 2024 * | 48.9 x |
| Net cash position 2024 * | 5.7M 3.66M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 24.2 x |
| P/E ratio 2024 * |
-19.5
x | P/E ratio 2025 * |
-26.6
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.87% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.68% | ||
| 1 week | -8.40% | ||
| Current month | -5.22% | ||
| 1 month | +15.34% | ||
| 3 months | +36.25% | ||
| 6 months | +19.78% | ||
| Current year | +21.79% |
1 week
1.09
1.20
1 month
1.011.30
Current year
0.771.40
1 year
0.701.40
3 years
0.611.40
5 years
0.201.48
10 years
0.151.48
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 14-06-08 | |
Jacqueline Gray
DFI | Director of Finance/CFO | - | 21-07-11 |
Kirsten Peters
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul House
BRD | Director/Board Member | - | 17-11-21 |
Robyn Elliott
BRD | Director/Board Member | 63 | 21-11-15 |
| Founder | - | 14-06-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.09 | -2.68% | 156,209 |
| 24-04-18 | 1.12 | -3.45% | 206,828 |
| 24-04-17 | 1.16 | +4.50% | 143,397 |
| 24-04-16 | 1.11 | -2.63% | 163,016 |
| 24-04-15 | 1.14 | -5.79% | 313,620 |
Delayed Quote Australian S.E., April 19, 2024 at 01:58 am EDT
More quotes
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bio-analytical services. The Company specializes in proteomics, the study of the structure and function of proteins. The Company focuses on developing and commercializing diagnostic tests for chronic diseases. The Company operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. The PromarkerD test system is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Its Analytical Services includes a proteomics-based technology platform, used to test, and validate the protein composition of varied range of products.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.09
AUD
Average target price
1.38
AUD
Spread / Average Target
+26.61%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +21.79% | 94.4M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- PIQ Stock
